Alex C. Spyropoulos, MD received his medical degree from the University of Pennsylvania School of Medicine in Philadelphia, PA. He completed his internship and residency in internal medicine at the University of New Mexico Health Sciences Center in Albuquerque, NM. He is board certified in Internal Medicine.
Dr. Spyropoulos was Founder and former Medical Director of the Clinical Thrombosis Center in Albuquerque, New Mexico. He is a Professor of Medicine at Hofstra, Northwell School of Medicine and System Director of Anticoagulation and Clinical Thrombosis Services for the multi hospital Northwell Health System in NY. He is also a Professor of the Center for Health Innovations and Outcomes Research as part of the Feinstein Institute for Medical Research. He is co-chair of the Council on Leadership of Thrombosis at Northwell Health System. He is a Fellow of the American College of Physicians, American College of Chest Physicians, International Academy of Clinical and Applied Thrombosis/Haemostasis, and the Royal College of Physicians, Canada.
Dr. Spyropoulos has helped to develop protocols using LMWH in outpatient-based treatment of venous thromboembolic disease, patient self-testing of warfarin, perioperative “bridging” for patients on chronic anticoagulation, medical inpatient thromboprophylaxis, protocols with regards to the use of anticoagulants for HIT, and clinical use of the direct oral anticoagulants (DOAC), including their use in special patient populations and periprocedural situations. Dr. Spyropoulos is active in assessing outcome and pharmacoeconomic analyses of these protocols and has lectured extensively both nationally and internationally on these issues.
He has been involved as Principal Investigator, Scientific Committee member, Steering and Executive Committee member, or member of Data Safety Monitoring Board in multiple international, multicenter randomized trials in thrombosis and anticoagulant therapy, including the NHLBI BRIDGE and NHLBI Kids DOTT studies and the CIHR PAUSE trial. He was the co-Principal Investigator for MARINER, a global Phase 3 multicenter study of thromboprophylaxis in medical patients. He is a founding member of ATLAS, a US-based ARO-CRO in thrombosis-related research. He is a panel member of a US national experts consensus group for clinical excellence in thrombosis management, a Steering Committee member for World Thrombosis Day as part of the International Society of Thrombosis and Haemostasis (ISTH), he is Chair of the Scientific and Standardization Committee of ISTH on the Diagnosis, Prevention, and Treatment of COVID-19 Thrombosis, a member of the Global COVID-19 Thrombosis Collaborative Group, co-Chair of the Scientific and Standardization Committees of Perioperative Thrombosis and Haemostasis of ISTH, a member of the Anticoagulation Forum and the Thrombosis/Haemostasis Society of North America, , and co-author for the 8th, 9th and currently 10th 2020 ACCP Guidelines on Perioperative Antithrombotic Therapy, co-author of the 2008 International Consensus Statement Guidelines in Venous Thromboembolism, and senior author for the 2013 International Consensus Statement on venous thromboembolic disease. He is also reviewer for the 2014 ESC Guidelines on Pulmonary Embolism and the 2020 American College of Physicians Statement on Pulmonary Embolism Treatment.
Dr Spyropoulos has been very active in thrombosis-related issues with COVID-19 disease. He chaired the 2020 Guidance Statement of Scientific and Standardization Committee of the ISTH for the diagnosis, prevention, and treatment of VTE in hospitalized COVID-19 patients. He was an active member of the Global COVID-19 Thrombosis Collaborative Group which has published 2 major international guidance statements in COVID-19 and thrombosis-related issues. He is the Principal Investigator of the Hep-COVID trial, an investigator-initiated multicenter randomized controlled trial comparing treatment-dose LMWH versus standard-of-care prophylactic or intermediate-dose heparin in the prevention of major thromboembolism and death in sick hospitalized COVID-19 patients. He is also Principal Investigator of the CORE-19 registry, one of the largest registries of 11,200 patients assessing thromboembolic and other outcomes both in-hospital and post-discharge for COVID-19 patients. He is an Executive Committee member of the PREVENT-HD trial, a large 4000-5000 patients placebo-controlled randomized trial assessing the efficacy and safety of thromboprophylaxis using a DOAC in sick outpatients with COVID-19. He is the lead investigator in a large thromboembolic outcome study of over 10.871 hospitalized COVID-19 patients at Northwell Health. He has published over 10 articles, editorials, and letters for major journals related to COVID-19 and thrombosis.
He is Section Editor for Thrombosis and Haemostasis, and is on the editorial staff for Hospital Medicine. He is a reviewer for many journals.
Dr. Spyropoulos’ research studies, articles, letters, and editorials have been published in over 220 peer-reviewed journals including The New England Journal of Medicine, Blood, Blood Advances, Circulation, Lancet Hematology, Lancet, Annals of Internal Medicine, American Journal of Hematology, JAMA Internal Medicine, American Journal of Medicine, Journal of the American Heart Association, Chest, Thrombosis Haemostasis, American Journal of Cardiology, Journal of Thrombosis and Haemostasis, Journal of the American College of Cardiology, Clinical Applied Thrombosis and Haemostasis, and Thrombosis Research.
